Yael Weiss, MD, PhD

Yael Weiss received an MD at the Hebrew University in Jerusalem and her PhD in molecular genetics at the Weizmann Institute of Science (Rehovot, Israel). She has more than 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck, and Ultragenyx. In 2020, Yael founded Mahzi Therapeutics to bring therapies to patients with underserved rare genetic neurodevelopmental disorders. Mahzi – which means together in Greek – works closely with patient/family led Foundations to support their drug development efforts and brings therapeutic programs into Mahzi once pre-clinical proof of concept has been established.

Yael is a member of the NIH-driven Bespoke Gene Therapy (BCTG) consortium, the American Society of Gene and Cell Therapy Translational Committee, the N=1 Collaborative, and a 2022 Termeer Fellow. She is a board member/advisor to the ADNP and FOXG1 Foundations.